New combo therapy offers hope for hard-to-treat bone marrow cancer

NCT ID NCT05393674

Completed Disease control Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest Source: ClinicalTrials.gov ↗

First seen Jan 11, 2026 · Last updated May 02, 2026 · Updated 16 times

Summary

This study tested a combination of two drugs, fedratinib and nivolumab, in 30 adults with myelofibrosis (a type of bone marrow cancer) whose disease did not respond well to standard JAK-inhibitor therapy. The goal was to see if the combination could shrink the spleen, improve symptoms, or reduce the need for blood transfusions. The study is now complete, and results will help determine if this approach is effective and safe for patients who have limited options.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY MYELOFIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Johannes Wesling Klinikum

Minden, Germany
Medizinische Hochschule

Hanover, Germany
Uniklinik Ulm

Ulm, Germany
University Medicine Greifswald

Greifswald, Germany
Universitätsklinikum Freiburg

Freiburg im Breisgau, Germany
Universitätsklinikum Halle (Saale)

Halle, Germany
Universitätsklinikum Schleswig-Holstein

Lübeck, Germany

Conditions

Explore the condition pages connected to this study.

PRIMARY MYELOFIBROSIS SECONDARY MYELOFIBROSIS